An Open Label, Phase 1B Safety Evaluation of Patritumab (U31287) in Combination With Cetuximab Plus Platinum Containing Therapy In Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2017
At a glance
- Drugs Patritumab (Primary) ; Carboplatin; Cetuximab; Cisplatin
- Indications Head and neck cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 23 Aug 2016 Status changed from active, no longer recruiting to completed.
- 11 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Jun 2015 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016, as reported by ClinicalTrials.gov.